The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his ...

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ...

Healthy people who suffer traumatic spinal injuries are at significantly greater risk for long-term chronic health conditions ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Company cuts 9,000 jobs and lowers profit forecast as Wegovy sales slow. Q3 operating profit down 30% on competition ...

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

Taylor Swift Just Gave Some of the Best Advice You’ll Ever Hear, and It All Comes Down to a Simple Mindset Shift ...

Novo Nordisk has lowered its full-year profit and sales forecasts amid slowed sales growth. However, a better-than-expected ...

Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...

Novo Nordisk once dominated the weight-loss drug market with Wegovy. However, rising competition, particularly from Eli Lilly ...

In a small study, patients who have successfully lost weight with weekly GLP-1 treatment maintain their weight loss and ...